
It’s not the biggest publicly traded company in the world right now. That honor still belongs to Apple with a market cap if just under $3.5 trillion. That’s followed closely by Nvidia, currently worth $3.4 trillion. Microsoft isn’t far behind at $3.2 trillion.
Still, now at a $1 trillion valuation, Warren Buffett’s Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) is no slouch. Matching — or eclipsing — its size would be a considerable accolade.
With that as the backdrop, here’s a closer look at three names that could be worth more than Berkshire Hathaway just five years from now.
Berkshire Hathaway is hardly doomed. It’s not even expected to lose value. Indeed, it’s likely to grow its way to a larger market capitalization over the course of the coming five years.
There is something startling about Berkshire at this time, though — a concern that’s likely to linger for the foreseeable future. That’s a lack of opportunities that interest Buffett and his lieutenants. As of the most recent look, the conglomerate is sitting on more cash than stock holdings, while its privately held companies like Geico insurance, flooring company Shaw, Duracell batteries, and Fruit of the Loom (just to name a few) make up the single biggest sliver of Berkshire’s current capitalization.
Without explicitly saying as much, the Oracle of Omaha would rather invest in nothing new at this time than be forced to step into a bunch of holdings he doesn’t see much reason in owning for the foreseeable future.
Just because few companies work as part of Berkshire Hathaway’s value portfolio, however, it doesn’t mean there aren’t some that could be at home in yours as a growth holding. Here’s a closer look at some of these prospects.
You almost certainly know the company is a drugmaker. What you may not realize is just how much of Eli Lilly‘s (NYSE: LLY) current revenue comes from its diabetes treatment Mounjaro and its weight-loss drug Zepbound. Last quarter, these products accounted for a respective 27% and 11% of the pharmaceutical giant’s business.
Under normal circumstances, this degree of imbalance could eventually prove problematic. Not only does it leave a company too dependent on one or two particular profit centers, proven market opportunities like these also attract competitors.
These aren’t normal circumstances, though. Mounjaro along with Zepbound — both of which are the exact same molecular formula, called tirzepatide — are still just getting started. Research and analytics outfit GlobalData predicts annual sales of Mounjaro could peak somewhere between $27 billion and $34 billion by 2029, versus its current annualized revenue run rate of just over $12 billion.